What TQ Therapeutics does

TQ Therapeutics GmbH (TQx) is a private German biotech founded in 2023 and headquartered in Planegg near Munich. The company develops the proprietary CELLfinity™ platform built around its EXiVO (Extracorporeal in-vivo) approach, which combines elements of ex-vivo cell therapy and in-vivo gene therapy to manufacture autologous mRNA T-cell therapeutics. The modular stack integrates T-FABfinity™ affinity/column-based CD3+ T-cell selection (under two hours, residual-free), FABtivate™ Streptactin-based anti-CD3/CD28 activation reagents, and the CELLbricator™ automated drug-delivery system, supporting both non-viral (mRNA-LNP) and viral/CRISPR-Cas modification routes via two manufacturing workflows, CELLbricate™ ULTRA and CELLbricate™ PRO.

The company has five disclosed pipeline programs: TQ-1001 (autoimmune, CD19), TQ-1002 (infectious disease, stable integration), TQ-1003 (hemato-oncology, CARTemis anti-CXCR5), TQ-1004 (neurology, CAAR), and TQ-1005 (longevity, CD57/LNP). In May 2025 TQ acquired Juno Therapeutics GmbH from Bristol Myers Squibb, making BMS a financial backer alongside HTGf and Ventura. It subsequently joined the EU-funded EASYGEN consortium (€8M IHI, 18 partners, 8 countries), signed a technology access deal with Kytopen (Flowfect Tx®), and entered a strategic development agreement with Fresenius Kabi (January 2026).

TQ is pre-commercial with no disclosed pricing or revenue. Its business model is twofold: future product revenue from approved autologous CAR-T/CAAR therapeutics, and platform/licensing revenue from technology access and co-development agreements with pharmaceutical partners. The go-to-market is enterprise B2B via strategic pharma partnerships and decentralized hospital-based point-of-care manufacturing. Key risks are clinical/regulatory (preclinical pipeline), manufacturing scale-up, and partner concentration; key strengths are proprietary platform IP, a deep CAR-T scientific advisory bench, and anchor strategic investors including BMS and Fresenius Kabi.

Name

TQ Therapeutics

Legal name

TQ Therapeutics GmbH

Website

https://tqtherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

TQ Therapeutics is a German pre-clinical biotech developing the CELLfinity™ platform and EXiVO approach for decentralized, automated manufacturing of autologous mRNA CAR-T and gene-modified cell therapies across autoimmune, oncology, infectious, neurology, and longevity indications.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Cell therapy manufacturing
• Gene therapy platforms
• CAR-T therapeutics
• Autologous cell engineering
• Biopharmaceutical manufacturing

Headquarters

HQ city

Planegg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Cell & Gene Therapy Products: Pre-commercial stage. The company is developing a pipeline of in-vivo CAR-T therapeutics for autoimmune diseases, infectious diseases, neurological disorders, and hemato-oncology. Revenue will be generated from therapeutic products once approved and commercialized.
2. Technology Licensing & Platform Access: Technology access agreements with partners such as Kytopen and Fresenius Kabi may generate licensing revenue for platform access and co-development arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TQ Therapeutics develops and manufactures autologous cell and gene therapies using its proprietary CELLfinity™ platform built on the EXiVO (Extracorporeal in-vivo) approach, which combines ex-vivo cell selection with in-vivo gene therapy concepts. The company's pipeline includes five therapeutic programs (TQ-1001 through TQ-1005) targeting autoimmune diseases, infectious diseases, hemato-oncology, neurology, and longevity applications, supported by modular manufacturing processes (CELLbricate™ PRO and ULTRA), T-FABfinity™ cell selection, FABtivate™ activation reagents, and the CELLbricator™ automated delivery device designed for decentralized hospital-based production.

Product overview

TQ Therapeutics is a cell and gene therapy company developing the TQx CELLfinity™ platform based on its proprietary EXiVO (Extracorporeal in-vivo) approach, which combines the benefits of ex-vivo cell therapy and in-vivo gene therapy. The platform consists of CELLbricate™ ULTRA and CELLbricate™ PRO manufacturing processes, supported by T-FABfinity™ cell selection technology and FABtivate™ activation reagents, enabled through the CELLbricator™ drug delivery system. The company's pipeline includes five programs (TQ-1001 through TQ-1005) targeting autoimmune diseases, infectious diseases, oncology, neurology, and longevity applications, utilizing various transfection methods including LNPs, viral vectors, and CRISPR-CAS.

Differentiator

Problem solved

Functional benefit

Products and services

• CELLfinity™ Platform Proprietary modular target cell-specific modification platform for generating cell and gene therapy products, encompassing drug delivery systems, cell selection, activation, and genetic modification technologies. Offered to pharmaceutical partners for co-development of decentralized autologous cell therapies.
• CELLbricator™ System Automated drug delivery application device enabling the CELLbricate™ PRO and ULTRA processes by combining highly automated targeted cell selection and genetic manipulation within one step, intended for hospital-based point-of-care cell therapy manufacturing.
• CELLbricate™ ULTRA Manufacturing Process Five-step manufacturing workflow for whole blood collection, target cell selection using T-FABfinity™ technology, genetic modification via mRNA-LNP (non-viral), in-process analytics, and reinfusion of the EXiVO cell product. Designed for decentralized autologous cell therapy production.
• CELLbricate™ PRO Manufacturing Process Advanced manufacturing workflow combining T-FABfinity™ cell selection with FABtivate™ activation reagent, supporting both viral and non-viral genetic modification methods alongside in-process analytics and reinfusion steps. Designed for decentralized autologous cell therapy production.
• TQ-1001 (Autoimmune CAR-T Program) EXiVO-derived in-vivo CAR-T therapeutic candidate for autoimmune diseases, using lipid nanoparticles (LNPs) for transient transfection of CD3+ T cells targeting CD19 to deplete pathogenic B cells. Pipeline program for B-cell-mediated autoimmune indications such as rheumatoid arthritis and systemic lupus erythematosus.
• TQ-1002 (Infectious Disease Cell Therapy) In-vivo cell therapy candidate for infectious diseases, using viral transfection with stable integration to engineer CD3+ T cells. Part of TQ's pipeline addressing unmet needs in infectious disease therapeutics.
• TQ-1003 (Hemato-Oncology CAR-T with CARTemis) CAR-T therapy candidate for hematologic malignancies, using CRISPR-Cas technology with TQ's proprietary anti-CXCR5 CARTemis CAR construct to target CD3+ T cells.
• TQ-1004 (Neurology CAAR Program) Chimeric AutoAntigen Receptor (CAAR) cell therapy candidate targeting neurology indications, part of TQ's pipeline extending the EXiVO approach beyond oncology and autoimmune disease.
• TQ-1005 (Longevity Therapeutic) Longevity therapeutic candidate using lipid nanoparticles (LNPs) to target CD57 cells, representing TQ's exploration of aging-related applications of the CELLfinity™ platform.

Quantifiable outcome

• CAR T manufacturing time reduced to under 24 hours
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Fresenius KabicoreStrategic or Co-development Partner · 28 January 2026Strategic development agreement to develop scalable cell therapy manufacturing technologies. Partnership aims to create an automated system that isolates T cells in less than two hours to advance cell and gene therapy accessibility.
• EASYGEN ConsortiumcoreStrategic or Co-development Partner · 8 December 2025European consortium of 18 academic, research, industry, and clinic partners across 8 countries developing an automated, modular point-of-care manufacturing platform for CAR T-cell cancer therapy. Backed by €8 million EU funding from the Innovative Health Initiative. TQ Therapeutics is an industry partner in this flagship initiative.
• KytopencoreTechnology or Integration · 2 December 2025Technology access agreement providing access to Kytopen's Flowfect Tx® cellular engineering platform. Collaboration aims to integrate Kytopen's technology into TQ's CELLfinity platform to accelerate development of autologous mRNA T-cell therapies.
• Juno Therapeutics GmbHcoreStrategic or Co-development Partner · 28 May 2025Acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics from Bristol Myers Squibb through a share purchase agreement. Acquisition supports development of TQx's decentralized, automated cell and gene therapy platform.
• Pantherna TherapeuticsstrategicStrategic or Co-development PartnerResearch collaboration to advance ultra-short Cell and Gene Therapy (CGT) process leveraging LNP (Lipid Nanoparticle) technology. Aims to develop innovative manufacturing approaches for cell and gene therapy.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MaxCyte: Public US company providing electroporation-based Flowfect cell engineering technology used in autologous and allogeneic cell therapy manufacturing. Directly comparable to TQ's process since TQ has integrated a competing cell engineering platform (Kytopen Flowfect Tx) into its own CELLfinity workflow.
• Cellectis: Clinical-stage French biotech developing allogeneic CAR-T therapies using proprietary TALEN gene editing. Comparable as a European cell therapy developer with a platform approach to engineering T cells, though Cellectis focuses on allogeneic rather than autologous manufacturing.
• Adaptimmune: Clinical-stage cell therapy company developing engineered T-cell receptor therapies for solid tumors and autoimmune disease. Comparable as a European/US cell therapy developer with a focus on engineered autologous T cells, including autoimmune indications like TQ-1001's target.
• Miltenyi Biotec: Privately held German manufacturer of cell selection, activation, and processing technologies for autologous cell therapy manufacturing. Directly comparable to TQ's T-FABfinity cell selection and FABtivate activation reagents, serving the same hospital and academic GMP cell therapy workflow.

Others

• Cytiva: Large-scale provider of cell therapy manufacturing equipment, consumables, and automation solutions including the Sefia and Sepax systems. Comparable to TQ's CELLbricator system as an enabler of cell therapy manufacturing workflows, though Cytiva serves broader bioprocessing customers.

Emerging players

• Umoja Biopharma: US-based clinical-stage biotech developing in-vivo CAR-T therapies using lentiviral gene delivery. Closely comparable to TQ's EXiVO in-vivo CAR-T approach, particularly for autoimmune and oncology indications, though Umoja's delivery method differs from TQ's mRNA-LNP.
• Kytopen: MIT-spinout developing Flowfect technology for continuous-flow cellular engineering, with a specific Flowfect Tx platform for therapeutic cell manufacturing. Both a direct technology peer (comparable gene editing/delivery focus) and an existing TQ commercial partner under their 2025 technology access agreement.
• Capstan Therapeutics: US-based biotech developing in-vivo cell therapies using mRNA-LNP delivery to reprogram immune cells, including CAR-T for autoimmune disease. Closely comparable to TQ's EXiVO approach and TQ-1001 autoimmune CD19 program, representing direct modality competition.
• Orgenesis: Cellular therapy company pursuing decentralized point-of-care manufacturing of autologous therapies through its POCare platform. Directly comparable to TQ's decentralized manufacturing thesis, though Orgenesis has historically focused on different indications and a different regional footprint.

Broad incumbents

• Lonza: Global contract development and manufacturing organization (CDMO) with a leading Cell & Gene Technologies business offering autologous and allogeneic cell therapy manufacturing services. Comparable as a competing manufacturing platform provider, though Lonza operates a centralized rather than decentralized model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tq-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TQ Therapeutics